Stock News

Boston Scientific (BSX) Reaches $30.35 52-Week High; Price T Rowe Associates Has Decreased By $33.10 Million Its Santander Consumer Usa Hdg I (SC) Stake

Santander Consumer USA Holdings Inc. (NYSE:SC) Logo

The stock of Boston Scientific Corporation (NYSE:BSX) hit a new 52-week high and has $31.26 target or 3.00% above today’s $30.35 share price. The 9 months bullish chart indicates low risk for the $41.87B company. The 1-year high was reported on May, 17 by Barchart.com. If the $31.26 price target is reached, the company will be worth $1.26 billion more. The stock increased 1.27% or $0.3816 during the last trading session, reaching $30.3516. About 3.95M shares traded. Boston Scientific Corporation (NYSE:BSX) has risen 9.97% since May 17, 2017 and is uptrending. It has underperformed by 1.58% the S&P500.

Price T Rowe Associates Inc decreased Santander Consumer Usa Hdg I (SC) stake by 38.34% reported in 2017Q4 SEC filing. Price T Rowe Associates Inc sold 1.84M shares as Santander Consumer Usa Hdg I (SC)’s stock declined 13.77%. The Price T Rowe Associates Inc holds 2.96M shares with $55.06M value, down from 4.80M last quarter. Santander Consumer Usa Hdg I now has $7.13B valuation. The stock decreased 0.10% or $0.02 during the last trading session, reaching $19.74. About 616,493 shares traded. Santander Consumer USA Holdings Inc. (NYSE:SC) has risen 23.52% since May 17, 2017 and is uptrending. It has outperformed by 11.97% the S&P500.

Among 32 analysts covering Boston Scientific Corporation (NYSE:BSX), 26 have Buy rating, 0 Sell and 6 Hold. Therefore 81% are positive. Boston Scientific Corporation has $36 highest and $19 lowest target. $30.26’s average target is -0.30% below currents $30.3516 stock price. Boston Scientific Corporation had 99 analyst reports since July 27, 2015 according to SRatingsIntel. On Thursday, July 27 the stock rating was maintained by Cowen & Co with “Buy”. Raymond James downgraded Boston Scientific Corporation (NYSE:BSX) on Monday, October 5 to “Strong Buy” rating. Jefferies maintained Boston Scientific Corporation (NYSE:BSX) on Tuesday, September 5 with “Hold” rating. SunTrust maintained Boston Scientific Corporation (NYSE:BSX) on Friday, December 1 with “Buy” rating. The firm has “Hold” rating by Oppenheimer given on Wednesday, June 28. Citigroup initiated Boston Scientific Corporation (NYSE:BSX) on Thursday, November 12 with “Buy” rating. BMO Capital Markets maintained it with “Buy” rating and $31.0 target in Wednesday, November 29 report. The stock has “Buy” rating by Benchmark on Thursday, July 23. The rating was maintained by Needham with “Buy” on Thursday, July 27. The stock has “Hold” rating by BTIG Research on Monday, June 26.

Analysts await Boston Scientific Corporation (NYSE:BSX) to report earnings on July, 26. They expect $0.34 EPS, up 6.25% or $0.02 from last year’s $0.32 per share. BSX’s profit will be $469.03M for 22.32 P/E if the $0.34 EPS becomes a reality. After $0.33 actual EPS reported by Boston Scientific Corporation for the previous quarter, Wall Street now forecasts 3.03% EPS growth.

More notable recent Boston Scientific Corporation (NYSE:BSX) news were published by: Forbes.com which released: “A Quick Snapshot Of Boston Scientific’s Rhythm Management & Neuro Segment” on May 16, 2018, also Streetinsider.com with their article: “JANA Shows New Stakes in Apple (AAPL), Boston Scientific (BSX), Dropbox (DBX), iQIYI (IQ) (more..) -13F” published on May 15, 2018, Seekingalpha.com published: “Highlights from Appaloosa’s Q1” on May 15, 2018. More interesting news about Boston Scientific Corporation (NYSE:BSX) were released by: Benzinga.com and their article: “Jim Cramer Gives His Opinion On Boston Scientific, Lennar And Discover Financial” published on May 17, 2018 as well as Streetinsider.com‘s news article titled: “Pre-Open Movers 05/14: (ACIA) (SHLD) (NXPI) Higher; (XRX) (DF) (BSX) Lower (more…)” with publication date: May 14, 2018.

Boston Scientific Corporation develops, makes, and markets medical devices for use in various interventional medical specialties worldwide. The company has market cap of $41.87 billion. It operates through three divisions: Cardiovascular, Rhythm Management, and MedSurg. It has a 399.36 P/E ratio. The firm offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; other coronary therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Since December 29, 2017, it had 0 insider purchases, and 17 insider sales for $8.68 million activity. $931,680 worth of stock was sold by Ballinger Kevin J. on Monday, May 7. Shares for $60,786 were sold by Sorenson John Bradley. $102,600 worth of Boston Scientific Corporation (NYSE:BSX) was sold by Pierce David A. $2.26M worth of stock was sold by Fitzgerald Joseph Michael on Wednesday, February 7. $399,865 worth of Boston Scientific Corporation (NYSE:BSX) was sold by Phalen Michael P.. Butcher Arthur C had sold 7,500 shares worth $225,413 on Thursday, May 10. Brennan Daniel J. had sold 60,209 shares worth $1.68 million on Monday, March 19.

Investors sentiment increased to 1.34 in Q4 2017. Its up 0.30, from 1.04 in 2017Q3. It increased, as 36 investors sold Boston Scientific Corporation shares while 158 reduced holdings. 86 funds opened positions while 174 raised stakes. 1.18 billion shares or 2.38% less from 1.21 billion shares in 2017Q3 were reported. Fred Alger Mgmt stated it has 3.22M shares. Piedmont Investment Limited Com has 0.15% invested in Boston Scientific Corporation (NYSE:BSX). Caxton Assoc Limited Partnership accumulated 44,975 shares. Sirios Management Ltd Partnership holds 3.23% or 2.63M shares. 6,197 are held by Winslow Mgmt Ltd Liability Company. Nomura reported 298,712 shares. Neuberger Berman Group Inc reported 0.17% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Moreover, Keybank National Association Oh has 0% invested in Boston Scientific Corporation (NYSE:BSX) for 14,931 shares. Putnam Investments Ltd has 9.64M shares. Sun Life Fincl holds 0.01% or 3,008 shares. Anchor Advsr Limited has invested 0.7% in Boston Scientific Corporation (NYSE:BSX). Natl Bank stated it has 37,530 shares or 0.01% of all its holdings. Nuveen Asset Ltd reported 97,044 shares. Bainco Int Investors reported 0.63% in Boston Scientific Corporation (NYSE:BSX). Nomura Asset Mngmt Limited holds 267,443 shares.

Investors sentiment increased to 1.86 in 2017 Q4. Its up 0.68, from 1.18 in 2017Q3. It improved, as 12 investors sold SC shares while 47 reduced holdings. 50 funds opened positions while 60 raised stakes. 113.36 million shares or 0.10% more from 113.25 million shares in 2017Q3 were reported. Ubs Asset Americas reported 0% of its portfolio in Santander Consumer USA Holdings Inc. (NYSE:SC). Secor Cap Advsrs LP has 89,134 shares. Paloma Ptnrs holds 18,182 shares or 0% of its portfolio. Jacobs Asset Mgmt Lc holds 2.17% or 615,447 shares in its portfolio. California State Teachers Retirement Systems holds 0.01% or 258,212 shares. Texas-based Dimensional Fund Advsrs Lp has invested 0.04% in Santander Consumer USA Holdings Inc. (NYSE:SC). Walleye Trading Ltd Liability holds 0.04% of its portfolio in Santander Consumer USA Holdings Inc. (NYSE:SC) for 413,456 shares. Rhumbline Advisers invested in 132,766 shares. Vident Inv Advisory Limited Liability Co, Georgia-based fund reported 10,399 shares. State Of Alaska Department Of Revenue invested 0% of its portfolio in Santander Consumer USA Holdings Inc. (NYSE:SC). Cibc Asset invested in 0% or 18,632 shares. Td Asset Mngmt reported 0% in Santander Consumer USA Holdings Inc. (NYSE:SC). Nuveen Asset Ltd Liability Corp reported 122,500 shares stake. Stevens Mgmt Lp reported 148,837 shares stake. Barclays Public holds 0.01% of its portfolio in Santander Consumer USA Holdings Inc. (NYSE:SC) for 650,006 shares.

Another recent and important Santander Consumer USA Holdings Inc. (NYSE:SC) news was published by Globenewswire.com which published an article titled: “New Research: Key Drivers of Growth for Comerica, Valley National, Santander Consumer, Sterling, Kemet, and …” on May 11, 2018.

Price T Rowe Associates Inc increased Five9 Inc (NASDAQ:FIVN) stake by 16,362 shares to 4.79M valued at $119.16 million in 2017Q4. It also upped Compania De Minas Buenaventu (NYSE:BVN) stake by 3.60M shares and now owns 4.20M shares. Senseonics Hldgs Inc was raised too.

Analysts await Santander Consumer USA Holdings Inc. (NYSE:SC) to report earnings on July, 27. They expect $0.74 earnings per share, up 5.71% or $0.04 from last year’s $0.7 per share. SC’s profit will be $267.32M for 6.67 P/E if the $0.74 EPS becomes a reality. After $0.67 actual earnings per share reported by Santander Consumer USA Holdings Inc. for the previous quarter, Wall Street now forecasts 10.45% EPS growth.

Among 25 analysts covering Santander Consumer USA Holdings (NYSE:SC), 12 have Buy rating, 0 Sell and 13 Hold. Therefore 48% are positive. Santander Consumer USA Holdings had 72 analyst reports since August 3, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, October 16 by Jefferies. The rating was maintained by RBC Capital Markets on Wednesday, June 14 with “Hold”. The stock of Santander Consumer USA Holdings Inc. (NYSE:SC) earned “Hold” rating by RBC Capital Markets on Monday, January 8. The firm earned “Buy” rating on Monday, October 30 by UBS. BMO Capital Markets maintained Santander Consumer USA Holdings Inc. (NYSE:SC) on Friday, October 27 with “Buy” rating. The company was maintained on Tuesday, April 24 by BTIG Research. On Wednesday, April 25 the stock rating was maintained by Barclays Capital with “Equal-Weight”. As per Tuesday, November 14, the company rating was maintained by Keefe Bruyette & Woods. BMO Capital Markets maintained Santander Consumer USA Holdings Inc. (NYSE:SC) rating on Friday, July 28. BMO Capital Markets has “Buy” rating and $1400 target. Citigroup maintained it with “Buy” rating and $14 target in Friday, April 1 report.

Santander Consumer USA Holdings Inc. (NYSE:SC) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *